1. Home
  2. POAI vs AYTU Comparison

POAI vs AYTU Comparison

Compare POAI & AYTU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • POAI
  • AYTU
  • Stock Information
  • Founded
  • POAI 2002
  • AYTU N/A
  • Country
  • POAI United States
  • AYTU United States
  • Employees
  • POAI N/A
  • AYTU N/A
  • Industry
  • POAI Industrial Specialties
  • AYTU Biotechnology: Pharmaceutical Preparations
  • Sector
  • POAI Health Care
  • AYTU Health Care
  • Exchange
  • POAI Nasdaq
  • AYTU Nasdaq
  • Market Cap
  • POAI 8.9M
  • AYTU 9.6M
  • IPO Year
  • POAI N/A
  • AYTU N/A
  • Fundamental
  • Price
  • POAI $0.80
  • AYTU $2.35
  • Analyst Decision
  • POAI Hold
  • AYTU Strong Buy
  • Analyst Count
  • POAI 1
  • AYTU 2
  • Target Price
  • POAI N/A
  • AYTU $10.00
  • AVG Volume (30 Days)
  • POAI 164.4K
  • AYTU 270.5K
  • Earning Date
  • POAI 08-12-2025
  • AYTU 05-14-2025
  • Dividend Yield
  • POAI N/A
  • AYTU N/A
  • EPS Growth
  • POAI N/A
  • AYTU N/A
  • EPS
  • POAI N/A
  • AYTU N/A
  • Revenue
  • POAI $1,729,269.00
  • AYTU $81,659,000.00
  • Revenue This Year
  • POAI $486.27
  • AYTU N/A
  • Revenue Next Year
  • POAI $65.50
  • AYTU $8.68
  • P/E Ratio
  • POAI N/A
  • AYTU N/A
  • Revenue Growth
  • POAI 24.17
  • AYTU 0.41
  • 52 Week Low
  • POAI $0.55
  • AYTU $0.95
  • 52 Week High
  • POAI $3.06
  • AYTU $2.91
  • Technical
  • Relative Strength Index (RSI)
  • POAI 32.97
  • AYTU 68.74
  • Support Level
  • POAI $0.73
  • AYTU $2.32
  • Resistance Level
  • POAI $0.86
  • AYTU $2.45
  • Average True Range (ATR)
  • POAI 0.05
  • AYTU 0.12
  • MACD
  • POAI -0.00
  • AYTU 0.02
  • Stochastic Oscillator
  • POAI 30.59
  • AYTU 84.62

About POAI Predictive Oncology Inc.

Predictive Oncology Inc functions in the healthcare domain. The firm's reportable segments are Pittsburgh segment that provides services which include the application of AI using its proprietary biobank of 150,000+ tumor samples. It also creates proprietary 3D culture models used in drug development; Birmingham segment that provides contract services and research focused on solubility improvements, stability studies, and protein production; and Eagan segment that produces the FDA-cleared STREAMWAY System and associated products for automated medical fluid waste management and patient-to-drain medical fluid disposal. It derives maximum revenue from Eagan Segment.

About AYTU Aytu BioPharma Inc.

Aytu BioPharma Inc is a specialty pharmaceutical company with a commercial portfolio of prescription therapeutics and consumer health products. The company's primary prescription products treat attention deficit hyperactivity disorder and other common pediatric conditions. It is building a complementary therapeutic development pipeline including a prospective treatment (AR101/enzastaurin) for vascular Ehlers-Danlos Syndrome, a rare genetic disease resulting in high morbidity and a significantly shortened lifespan. The company operates in two segments Rx Segment, consisting of prescription pharmaceutical products and Consumer Health segments of which the company generates maximum revenue from the Rx segment.

Share on Social Networks: